Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCA | P17252 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | BTN3A1 | O00481 | 3/20 | 0.33 |
| ▸ | SERPINE1 | P05121 | 1/20 | 0.32 |
| ▸ | ELANE | P08246 | 1/20 | 0.31 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1710583 | 0.92 | PRKCA (0.38) | PRKCAPOLBGAANPSR1BTN3A1 | |
| SCHEMBL5445288 | 0.85 | PRKCA (0.43) | PRKCAPOLBGAANPSR1BTN3A1 | |
| SCHEMBL1204159 | 0.79 | ALDH1A1 (0.40) | GAASERPINE1TRPA1ALDH1A1 | |
| SCHEMBL9348634 | 0.79 | PRKCA (0.44) | PRKCAPOLBGAANPSR1BTN3A1 | |
| SCHEMBL13686650 | 0.79 | PRKCA (0.39) | PRKCAPOLBGAANPSR1BTN3A1 | |
| SCHEMBL5493183 | 0.78 | — | — | |
| SCHEMBL24883882 | 0.77 | PRKCA (0.38) | PRKCAPOLBGAANPSR1SERPINE1 | |
| SCHEMBL6879319 | 0.77 | ALDH1A1 (0.39) | PRKCAPOLBGAANPSR1BTN3A1 | |
| SCHEMBL12571028 | 0.77 | PRKCA (0.38) | PRKCAPOLBGAANPSR1SERPINE1 | |
| SCHEMBL24877573 | 0.76 | PRKCA (0.37) | PRKCAPOLBGAANPSR1SERPINE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102245593-A | Isoquinolinone derivatives | ASTRAZENECA AB | 2011-11-16 | — | — | CN | disclosed |
| US-8012980-B2 | Isoquinolinone derivatives | ASTRAZENECA AB (SE) | 2011-09-06 | — | — | US | disclosed |
| EP-2344472-A1 | ISOQUINOLINONE DERIVATIVES | AstraZeneca AB (SE) | 2011-07-20 | — | — | EP | disclosed |
| US-20100099665-A1 | ISOQUINOLINONE DERIVATIVES | ASTRAZENECA AB (SE) | 2010-04-22 | — | — | US | disclosed |
| WO-2010039079-A1 | ISOQUINOLINONE DERIVATIVES | ASTRAZENECA AB (SE) | 2010-04-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100099665-A1 | ISOQUINOLINONE DERIVATIVES | SDHA, NQO1, CYP3A5 | PRKCA 2939/4885POLB 1234/4885GAA 876/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.